- Home
- CRIS vs GLYC Comparison
CRIS vs GLYC Comparison
Compare CRIS & GLYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- GLYC
- Stock Information
- Founded
- CRIS 2000
- GLYC 2003
- Country
- CRIS United States
- GLYC United States
- Employees
- CRIS 33
- GLYC N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- GLYC Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- GLYC Health Care
- Exchange
- CRIS Nasdaq
- GLYC Nasdaq
- Market Cap
- CRIS 13.5M
- GLYC 14.3M
- IPO Year
- CRIS 2000
- GLYC 2014
- Fundamental
- Price
- CRIS $1.50
- GLYC $0.24
- Analyst Decision
- CRIS Strong Buy
- GLYC Hold
- Analyst Count
- CRIS 3
- GLYC 3
- Target Price
- CRIS $21.00
- GLYC N/A
- AVG Volume (30 Days)
- CRIS 102.7K
- GLYC 417.4K
- Earning Date
- CRIS 05-06-2025
- GLYC 05-08-2025
- Dividend Yield
- CRIS N/A
- GLYC N/A
- EPS Growth
- CRIS N/A
- GLYC N/A
- EPS
- CRIS N/A
- GLYC N/A
- Revenue
- CRIS $10,908,000.00
- GLYC N/A
- Revenue This Year
- CRIS $2.33
- GLYC N/A
- Revenue Next Year
- CRIS $9.78
- GLYC N/A
- P/E Ratio
- CRIS N/A
- GLYC N/A
- Revenue Growth
- CRIS 8.83
- GLYC N/A
- 52 Week Low
- CRIS $1.02
- GLYC $0.14
- 52 Week High
- CRIS $16.99
- GLYC $2.05
- Technical
- Relative Strength Index (RSI)
- CRIS 37.70
- GLYC 56.22
- Support Level
- CRIS $1.06
- GLYC $0.21
- Resistance Level
- CRIS $1.30
- GLYC $0.22
- Average True Range (ATR)
- CRIS 0.15
- GLYC 0.02
- MACD
- CRIS 0.07
- GLYC 0.01
- Stochastic Oscillator
- CRIS 70.59
- GLYC 65.87
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About GLYC GlycoMimetics Inc.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.